Can recovery from depression be achieved?

Psychiatric Services

Volumn 52, Issue 11, 2001, Pages 1469-1478

  Shelton, R C ^a   Tomarken, A J ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; AMFEBUTAMONE; AMOXAPINE; AMPHETAMINE; ANTIDEPRESSANT AGENT; BUSPIRONE; CITALOPRAM; DESIPRAMINE; DOPAMINE; FLUOXETINE; FLUVOXAMINE; LITHIUM; MAPROTILINE; METHYLPHENIDATE; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NEUROLEPTIC AGENT; NORADRENALIN; NORADRENALIN UPTAKE INHIBITOR; OLANZAPINE; PHENELZINE; PSYCHOSTIMULANT AGENT; REBOXETINE; RISPERIDONE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANYLCYPROMINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE;

AFFECT; AFFECTIVE NEUROSIS; ANHEDONIA; ANXIETY NEUROSIS; ARTICLE; DEPRESSION; DISTRESS SYNDROME; DRUG MECHANISM; HUMAN; MOTIVATION; PANIC; REWARD; SYMPTOMATOLOGY;

ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; DEPRESSIVE DISORDER; HUMANS; MODELS, PSYCHOLOGICAL; NOREPINEPHRINE; SEROTONIN; SEROTONIN UPTAKE INHIBITORS;

EID: 0034759091     PISSN: 10752730     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ps.52.11.1469     Document Type: Article

References (101)

1. Lifetime prevalence of specific psychiatric disorders in three sites
2. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: Results from the National Comorbidity Survey
3. Major affective disorder as a recurrent illness: A critical review
4. NIMH/NIH consensus development conference statement on mood disorders: Pharmacological prevention of recurrences
5. The course, morbidity, and costs of depression
6. Time to recover, recovery, chronicity, and levels of psychopathology in major depression
7. Social fuctioning in depression: A review
8. The global burden of disease, 1990-2020
9. The global burden of mental disorders
10. Recovery from major depression: A 10-year prospective follow-up across multiple episodes
11. A Conceptualization and rationale for consensus definitions of terms in major depressive disorder: Remission, recovery, relapse, and recurrence
12. The clinical pharmacologic profile of reboxetine: Does it involve the putative neurobiological substrates of well being?
13. Testing a tripartite model: I. Evaluating the convergent and discriminant validity of anxiety and depression symptom subscales
14. Testing a tripartite model: II. Exploring the symptom structure of anxiety and depression in student, adult, and patient samples
15. Structural relationships among dimensions of the DSM-IV anxiety and mood disorders and dimensions of negative affect, positive affect, and autonomic arousal
16. Emotion, motivation, and anxiety: Brain mechanisms and psychophysiology
17. Fear and anxiety: Animal models and human cognitive psychophysiology
18. Tripartite model of anxiety and depression: Psychometric evidence and taxonomic implications
19. Comorbidity of anxiety and unipolar mood disorders
20. Mechanisms of action in the treatment of anxiety
21. Major depression and generalized anxiety disorder: Same genes, (partly) different environments?
22. Models of comorbidity for multifactorial disorders
23. Major depression and generalised anxiety disorder: Same genes, (partly) different environments - Revisited
24. The familial aggregation of common psychiatric and substance use disorders in the National Comorbidity Survey: A family history study
25. Genetics and developmental psychopathology: I. Phenotypic assessment in the Virginia Twin Study of Adolesent Behavioral Development
26. Stressful life events and major depression: Risk period, long-term contextual threat, and diagnostic specificity
27. Do anxiety and depression have a common pathophysiological mechanism?
28. Toward a consensual structure of mood
29. Serotonin dysfunction disorders: A behavioral neuro-chemistry perspective
30. Interactions between 5-hydroxytryptamine receptor subtypes: Is a disturbed receptor balance contributing to the symtomatology, of depression in humans?
31. Serotonergic modulation of learned helplessness
32. The effects of administration of mCPP on psychological, cognitive, cardiovascular, hormonal, and MHPG measurements in human volunteers
33. 1A receptors in the dorsal raphe and dorsal hippocampus in anxiety assessed by the behavioral effects of 8-OH-DPAT and S 15535 in a modified Geller-Seifter conflict model
34. SSRIs and SMRIs: Broad spectrum of efficacy beyond major depression
35. Therapeutic indications for serotonin-potentiating compounds: A hypothesis
36. Selective alteration of personality, and social behavior by serotonergic innervation
37. A Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy
38. The timing, specificity, and clinical prediction of tricyclic drug effects in depression
39. Conceptualizing a serotonin trait: A behavioral dimension of constraint
40. Serotonergic functioning correlates with positive and negative affect in psychiatrically healthy males
41. Neurobiological mechanisms in human anxiety: Evidence supporting central noradrenergic hyperactivity
42. Noradrenergic mechanisms in stress and anxiety: I. Preclinical studies
43. Noradrenergic mechanisms in stress and anxiety: II. Clinical studies
44. The noradrenergic system in pathological anxiety: A focus on panic with relevance to generalized anxiety and phobias
45. Noradrenaline systems in systems in the hypothalamus, amygdala, and locus coeruleus are involved in the provocation of anxiety: Basic studies
46. Treatment of outpatients with desipramine
47. Desipramine treatment in panic disorder
48. The jitteriness syndrome in panic disorder patients treated with antidepressants
49. Therapeutic effects of imipramine are counteracted by its metabolite, desipramine, in patients with generalized anxiety disorder
50. Neurobiology and the structure of personality: Dopamine, facilitation of incentive motivation, and extraversion
51. Dopamine and the structure of personality: Relation of agonist-induced dopamine activity, to positive emotionality
52. Selecting an antidepressant by using mechanism of action to enhance efficacy and avoid side effects
53. Extracellular dopamine, norepinephrine, and serotonin in the ventral tegmental area and nucleus accumbens of freely moving rats during intracerebral dialysis following systemic administration of cocaine and other uptake blockers
54. Norepinephrine microinjections in the hypothalamic paraventricular nucleus increase extracellular dopamine and decrease acetylcholine in the nucleus accumbens: Relevance to feeding reinforcement
55. Expression cloning of a cocaine- and antidepressant-sensitive human noradrenaline transporter
56. Oculomotor signs in a psychiatric population: A preliminary report
57. Role of locus coeruleus in attention and behavioral flexibility
58. 2B/2C receptor subtypes in the control of accumbal and striatal dopamine release elicited in vivo by dorsal raphe nucleus electrical stimulation
59. 2c receptor subtypes in the control of in vivo dopamine outflow in the rat striatum
60. 2C receptor subtypes and significance of the haloperidol dose used
61. Differential effects of acute and chronic fluoxetine administration on the spontaneous activity of dopaminergie neurones in the ventral tegmental area
62. Differential effects of chronic imipramine and fluoxetine on basal and amphetamine-induced extracellular dopamine levels in rat nucleus accumbens
63. Intracranial reward after Lilly 110140 (fluoxetine HCI): Evidence for an inhibitory role for serotonin
64. Effects of Lilly 110140 (fluoxetine) on self-stimulation behavior in the dorsal and ventral regions of the lateral hypothalamus in the mouse
65. Acute and chronic fluoxetine treatment decreases the sensitivity of rats to rewarding brain stimulation
66. Beyond symptoms: Social functioning and the new antidepressants
67. Development and validation of a social functioning scale, the social adaptation self-evaluation scale
68. The 7 habits of highly effective psychopharmacologists: II. Begin with the end in mind
69. Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia
70. Pharmacotherapy for major depression with melancholic features: Relative efficacy of tricyclic versus selective serotonin reuptake inhibitor antidepressants
71. Are two antidepressant mechanisms better than one?
72. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors
73. Newer antidepressants: Hypotheses and evidence
74. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression
75. Buspirone augmentation of a selective serotonin reuptake inhibitor: Efficacy in two depressed patients with comorbid, anxiety and type I alcohol dependence
76. Paroxetine/bupropion combination treatment for refractory depression
77. Columbia a typical depression: A subgroup of depressives with better response to MAOI than to tricyclic antidepressants or placebo
78. A typical depression: A valid clinical entity?
79. Rational drug use in the treatment of depression
80. A double-blind parallel study comparing fluoxetine with imipramine in the treatment of a typical depression
81. Fluoxetine versus phenelzine in a typical depression
82. A placebo-controlled study of fluoxetine versus imipramine in the acute treatment of a typical depression
83. Gepirone treatment of a typical depression: Preliminary evidence of serotonergic involvement
84. Strategies for treatment-resistant depression
85. Treatment options for refractory depression
86. Augmentation strategies in depression 2000
87. New approaches to the treatment of refractory depression
88. Depression with anxiety and a typical depression
89. 1A receptors
90. 1B, receptors: A novel target for lithium: Possible involvement in mood disorders
91. 1A receptors by lithium addition to antidepressant treatments
92. 1A HT receptors induces rapid antidepressant response
93. Augmentation strategies with serotonergic-noradrenergic combinations
94. Venlafaxine and bupropion combination therapy in a case of treatment-resistant depression
95. Dopaminergic agents and stimulants as antidepressant augmentation strategies
96. A novel augmentation strategy for treatment-resistant major depression
97. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression
98. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex
99. Cognitive-behavioral analysis system of psychotherapy: An interactional treatment approach for dysthymic disorder
100. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression